{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:57:58Z","timestamp":1793059078100,"version":"4.5.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clindermatol.2026.09.003","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:23:45Z","timestamp":1789169025000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Where the Future Lies: GLP-1 Receptor Agonists as Therapeutics for Dermatologic Comorbidities"],"prefix":"10.1016","author":[{"given":"Mikaela","family":"DeCoster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanthi","family":"Narla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2026.09.003_bib0001","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0002","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13578-025-01486-8","article-title":"Roles of glucagon-like peptide 1 receptor agonists in immune cell biology and autoimmune\/autoinflammatory diseases","volume":"15","author":"Deng","year":"2025","journal-title":"Cell Biosci"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0003","unstructured":"Narla S, Narla RR, Corbett JA. JAAD CME Part 1: Mechanism of Action of GLP-1 Receptor Agonists and Potential Pathways in Skin Health. Journal of the American Academy of Dermatology."},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0004","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11883-025-01319-6","article-title":"The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes","volume":"27","author":"Sheth","year":"2025","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2026.0859","article-title":"The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review","author":"Sheth","year":"2026","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0006","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1007\/s00125-011-2232-3","article-title":"Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis","volume":"54","author":"Hogan","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0007","doi-asserted-by":"crossref","first-page":"9100","DOI":"10.1038\/s41598-017-09898-4","article-title":"GLP-1\/Exendin-4 induces \u03b2-cell proliferation via the epidermal growth factor receptor","volume":"7","author":"Fusco","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0008","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2337\/diabetes.52.1.124","article-title":"Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor","volume":"52","author":"Buteau","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0009","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.diabres.2018.10.013","article-title":"Glucagon-like peptide-1 analogue liraglutide facilitates wound healing by activating PI3K\/Akt pathway in keratinocytes","volume":"146","author":"Nagae","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114050","article-title":"Pro-healing impact of liraglutide on skin wounds in normoglycemic mice","volume":"147","author":"Yue","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2025.171366","article-title":"Dulaglutide accelerates diabetic wound healing by suppressing Nrf2-dependent ferroptosis in diabetic mice","volume":"185","author":"Xi","year":"2025","journal-title":"Peptides"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2026.01.088","article-title":"JAAD CME Part 1: Mechanism of Action of GLP-1 Receptor Agonists and Potential Pathways in Skin Health","author":"Narla","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0013","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jss.2016.09.024","article-title":"Exendin-4, a glucagon-like peptide-1 analogue, accelerates diabetic wound healing","volume":"208","author":"Roan","year":"2017","journal-title":"The Journal of surgical research"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0014","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1089\/scd.2020.0137","article-title":"Combined Treatment with Bone Marrow-Derived Mesenchymal Stem Cells and Exendin-4 Promotes Islet Regeneration in Streptozotocin-Induced Diabetic Rats","volume":"30","author":"Song","year":"2021","journal-title":"Stem Cells Dev"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.metabol.2015.10.009","article-title":"Differential effects of GLP-1 receptor agonist on foam cell formation in monocytes between non-obese and obese subjects","volume":"65","author":"Tanaka","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0016","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1111\/jdv.20694","article-title":"The effects of GLP-1RA on inflammatory skin diseases: A comprehensive review","volume":"39","author":"Paschou","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0017","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1007\/s00125-011-2297-z","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology","volume":"54","author":"Drucker","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0018","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1007\/s00018-010-0396-5","article-title":"Glucagon-like peptide-1(1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytes","volume":"67","author":"Marx","year":"2010","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0019","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1097\/DSS.0000000000005187","article-title":"Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Cutaneous Biology: Implications for Skin Disease and Longevity","volume":"52","author":"Vyas","year":"2026","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0020","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s12020-025-04293-w","article-title":"GLP-1RA and the possible skin aging","volume":"89","author":"Paschou","year":"2025","journal-title":"Endocrine"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0021","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s00266-019-01397-3","article-title":"Profile of Adipose-Derived Stem Cells in Obese and Lean Environments","volume":"43","author":"Vyas","year":"2019","journal-title":"Aesthetic Plast Surg"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061505","article-title":"Associations between Adipokines in Arthritic Disease and Implications for Obesity","volume":"20","author":"M\u1d43\u1d9cDonald","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0023","doi-asserted-by":"crossref","first-page":"851","DOI":"10.5114\/aoms.2016.58928","article-title":"Obesity and inflammation: the linking mechanism and the complications","volume":"13","author":"Ellulu","year":"2017","journal-title":"Archives of medical science : AMS"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0024","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamadermatol.2026.0859","article-title":"The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review","volume":"162","author":"Sheth","year":"2026","journal-title":"JAMA Dermatology"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0025","series-title":"GLP-1 agonists and psoriasis: a potential novel therapeutic approach","author":"Truong","year":"2025"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0026","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s40261-021-01080-z","article-title":"Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study","volume":"41","author":"Pirro","year":"2021","journal-title":"Clinical drug investigation"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0027","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1111\/jocd.15217","article-title":"Ixekizumab treatment in patients with moderate-to-severe plaque psoriasis in a real-world clinical setting","volume":"21","author":"Demirel \u00d6\u011f\u00fct","year":"2022","journal-title":"Journal of Cosmetic Dermatology"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0028","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2026.1753","article-title":"Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial","author":"Lebwohl","year":"2026","journal-title":"JAMA Dermatology"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0029","article-title":"Combination Biologic and GLP-1 Receptor Agonist Therapy in Psoriasis","author":"Lewitt","year":"2026","journal-title":"Practical dermatology"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0030","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1007\/s13555-026-01812-z","article-title":"Effects of Tirzepatide on Metabolic Parameters in Patients with Psoriasis and Obesity: 24-Week Real-World Study","volume":"16","author":"Gisondi","year":"2026","journal-title":"Dermatology and Therapy"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0031","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/bjd\/ljaf346","article-title":"Glucagon-like peptide-1 receptor agonists and reduced mortality, cardiovascular and psychiatric risks in patients with psoriasis: a large-scale cohort study","volume":"194","author":"Olbrich","year":"2026","journal-title":"British Journal of Dermatology"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0032","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jaad.2026.03.023","article-title":"Risk of developing psoriatic arthritis in patients with psoriasis initiating treatment with glucagon-like peptide-1 receptor agonists: A population cohort study from the TriNetX collaborative network","volume":"95","author":"Feng","year":"2026","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0033","doi-asserted-by":"crossref","DOI":"10.1002\/art.70134","article-title":"Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity","author":"Merola","year":"2026","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0034","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jdin.2025.07.003","article-title":"Decreased incidence of hidradenitis suppurativa and psoriasis in diabetic patients treated with GLP-1 receptor agonists: A retrospective cohort study","volume":"22","author":"Ching","year":"2025","journal-title":"JAAD Int"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0035","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jamadermatol.2025.2723","article-title":"Glucagon-Like Peptide-1 Receptor Agonists in Hidradenitis Suppurativa","volume":"161","author":"Gouvrion","year":"2025","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0036","doi-asserted-by":"crossref","first-page":"178","DOI":"10.36849\/JDD.9586","article-title":"GLP-1 Receptor Agonists in Overweight and Obese Patients With Hidradenitis Suppurativa","volume":"25","author":"Encarnacion","year":"2026","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0037","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/ijd.70191","article-title":"Glucagon-Like Peptide-1 Receptor Agonists Are Associated With Reduced Disease Severity and Pain in Hidradenitis Suppurativa: A Retrospective Study","volume":"65","author":"Islam","year":"2026","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0038","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics18050605","article-title":"GLP-1 Receptor Agonists in Chronic Inflammatory Skin Diseases: Immunometabolic Mechanisms and Translational Perspectives","volume":"18","author":"Andrzejczak","year":"2026","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2026.156547","article-title":"The multifaceted role of GLP-1 in metabolic disorders, chronic inflammation, and aging: Mechanisms and therapeutic potential","volume":"178","author":"Li","year":"2026","journal-title":"Metabolism"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0040","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2026.1907","article-title":"GLP-1 Receptor Agonist Use and Clinical Outcomes in Patients With Hidradenitis Suppurativa","author":"Jastrz\u0105b-Mi\u015bkiewicz","year":"2026","journal-title":"JAMA Dermatology"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0041","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2026.1882","article-title":"GLP-1 Receptor Agonists in Hidradenitis Suppurativa-Emerging Opportunities for Comorbidity Management?","author":"Naik","year":"2026","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0042","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.jaad.2025.08.019","article-title":"Glucagon-like peptide-1 receptor agonists mitigate the risk of major adverse cardiovascular events in patients with atopic dermatitis and type 2 diabetes","volume":"93","author":"Braun","year":"2025","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2026.103796","article-title":"Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression","volume":"93","author":"Budini","year":"2026","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103680","article-title":"Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis","volume":"90","author":"Tzang","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0045","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-085304","article-title":"Weight regain after cessation of medication for weight management: systematic review and meta-analysis","volume":"392","author":"West","year":"2026","journal-title":"BMJ"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0046","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0047","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1016\/S0140-6736(25)02165-8","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial","volume":"406","author":"Horn","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0048","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMoa2505669","article-title":"Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes","volume":"393","author":"Rosenstock","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0049","unstructured":"Lilly. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. 2026."},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0050","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1056\/NEJMoa2504214","article-title":"Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial","volume":"393","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0051","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0052","series-title":"Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer\u2019s GLP-1 RA Berobenatide","year":"2026"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2026.108331","article-title":"GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies","volume":"230","author":"Wang","year":"2026","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0054","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1124\/pr.115.010629","article-title":"Amylin: Pharmacology, Physiology, and Clinical Potential","volume":"67","author":"Hay","year":"2015","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0055","doi-asserted-by":"crossref","first-page":"320","DOI":"10.7570\/jomes21071","article-title":"Amylin as a Future Obesity Treatment","volume":"30","author":"Dehestani","year":"2021","journal-title":"J Obes Metab Syndr"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0056","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0057","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1001\/jama.2026.0287","article-title":"Data on 3 New GLP-1 Drugs for Weight Loss That May Be Approved This Year","volume":"335","author":"Rubin","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(26)00125-7","article-title":"Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study","author":"Buse","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(26)00126-9","article-title":"Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study","author":"Aroda","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0060","unstructured":"The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg\/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular Disease. 2022."},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0061","doi-asserted-by":"crossref","first-page":"eabm9609","DOI":"10.1126\/science.abm9609","article-title":"A structural basis for amylin receptor phenotype","volume":"375","author":"Cao","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105862","article-title":"The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats","volume":"118","author":"Kuhre","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0063","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0140-6736(25)01185-7","article-title":"Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b\/2a randomised controlled study","volume":"406","author":"Dahl","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0064","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(25)01176-6","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial","volume":"406","author":"Gasiorek","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0065","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1001\/jama.2025.14392","article-title":"New Molecules and Indications for GLP-1 Medicines","volume":"334","author":"Gonzalez-Rellan","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0066","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1056\/NEJMoa2511774","article-title":"Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment","volume":"393","author":"Wharton","year":"2025","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0067","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1016\/S0140-6736(25)02165-8","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial","volume":"406","author":"Horn","year":"2025","journal-title":"The Lancet"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0068","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0069","article-title":"FDA Approves GLP-1 Obesity Pill Without Food or Water Restrictions","volume":"335","author":"Anderer","year":"2026","journal-title":"Jama"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0070","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/oby.70106","article-title":"Weekly Subcutaneous VK2735, a GIP\/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study","volume":"34","author":"Bays","year":"2026","journal-title":"Obesity (Silver Spring, Md)"},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0071","unstructured":"Roux CWl, Wharton S, Startseva E, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity. New England Journal of Medicine. 0."},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0072","unstructured":"A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase III Trial Evaluating Long-term Efficacy and Safety of Survodutide Weekly Injections in Adult Participants With Noncirrhotic Non-alcoholic Steatohepatitis\/Metabolic Dysfunction-associated Steatohepatitis (NASH\/MASH) and (F2) - (F3) Stage of Liver Fibrosis. 2024."},{"key":"10.1016\/j.clindermatol.2026.09.003_bib0073","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0140-6736(25)01185-7","article-title":"Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b\/2a randomised controlled study","volume":"406","author":"Dahl","year":"2025","journal-title":"The Lancet"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X26002294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X26002294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:23:17Z","timestamp":1790004197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X26002294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":73,"alternative-id":["S0738081X26002294"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2026.09.003","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Where the Future Lies: GLP-1 Receptor Agonists as Therapeutics for Dermatologic Comorbidities","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2026.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}